Physician profile
Janis Holt
NPI 1285667030
$4,996.60
in general payments reported to CMS, 2019-2025
23 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $474 · 2021: $529 · 2022: $625 · 2023: $1,763 · 2024: $825 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868 · Travel and Lodging: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.37 |
| Travel and Lodging | $1,091.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,739.06 | 2019-2025 | Lensx, Clareon, Argos |
| Abbvie INC. | $440.82 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $257.91 | 2020-2023 | Acthar |
| Allergan, INC. | $232.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $213.58 | 2019-2021 | |
| Rxsight INC | $153.70 | 2022 | |
| Biotissue Holdings INC. | $131.61 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $123.80 | 2019-2025 | Cequa |
| Horizon Therapeutics Plc | $121.46 | 2020-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.45 | 2019-2020 | |
| Sight Sciences, INC. | $104.50 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $67.03 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $61.63 | 2024 | Catalys System |
| Dompe US, INC. | $36.45 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $28.01 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $27.14 | 2019 | |
| Merz North America, INC. | $25.81 | 2021 | |
| Eyepoint US, INC. | $25.78 | 2019 | |
| Amgen INC. | $21.58 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $21.32 | 2022 | |
| Oyster Point Pharma, INC. | $21.24 | 2022 | |
| Kala Pharmaceuticals, INC. | $16.43 | 2021 | |
| Glaukos Corporation | $14.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janis Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.